HIV-1 vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction

mBio

Volumn 2, Issue 3, 2011, Pages

  Schmidt, Sarah ^a   Fritz, Joëlle V ^a   Bitzegeio, Julia ^a,b   Fackler, Oliver T ^a   Keppler, Oliver T ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b AARON DIAMOND AIDS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; PRIMAQUINE; PROTEIN BETA TRCP; PROTEIN CD317; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; VPU PROTEIN; ANTIMALARIAL AGENT; BST2 PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; LEUKOCYTE ANTIGEN; VIRUS PROTEIN; VPU PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; BIOSYNTHESIS; CELL DENSITY; CELL MIGRATION; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOCYTOSIS; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; TRANS GOLGI NETWORK; VIRION; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS IMMUNITY; VIRUS INDUCTION; VIRUS RELEASE; VIRUS VIRULENCE; CELL LINE; CELL MEMBRANE; DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; METABOLISM; PATHOGENICITY;

HUMAN IMMUNODEFICIENCY VIRUS 1; MAMMALIA;

ANTIGENS, CD; ANTIMALARIALS; CELL LINE; CELL MEMBRANE; ENDOCYTOSIS; GPI-LINKED PROTEINS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; PRIMAQUINE; PROTEIN TRANSPORT; TRANS-GOLGI NETWORK; VIRAL REGULATORY AND ACCESSORY PROTEINS;

EID: 84855187526     PISSN: None     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00036-11     Document Type: Article

References (68)

1. Song B. 2009. TRIM5alpha. Curr. Top. Microbiol. Immunol. 339:47-66.
2. Malim MH, Emerman M. 2008. HIV-1 accessory proteins- ensuring viral survival in a hostile environment. Cell Host Microbe 3:388-398.
3. 3. Kupzig S, et al. 2003. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 4:694-709.
4. Swiecki M, et al. 2011. Structural and biophysical analysis of BST-2/ tetherin ectodomains reveals an evolutionary conserved design to inhibit virus release. J. Biol. Chem. 286:2987-2997.
5. Schubert HL, et al. 2010. Structural and functional studies on the extracellular domain of BST2/tetherin in reduced and oxidized conformations. Proc. Natl. Acad. Sci. U. S. A. 107:17951-17956.
6. Yang H, et al. 2010. Structural insight into the mechanisms of enveloped virus tethering by tetherin. Proc. Natl. Acad. Sci. U. S. A. 107: 18428-18432.
7. Rollason R, Korolchuk V, Hamilton C, Schu P, Banting G. 2007. Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif. J. Cell Sci. 120:3850-3858.
8. Masuyama N, et al. 2009. HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin. J. Biol. Chem. 284:15927-15941.
9. Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-430.
10. Hinz A, et al. 2010. Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain. Cell Host Microbe 7:314-323.
11. Casartelli N, et al. 2010. Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog. 6:e1000955.
12. Kuhl BD, et al. 2010. Tetherin restricts direct cell-to-cell infection of HIV-1. Retrovirology 7:115.
13. Jolly C, Booth NJ, Neil SJ. 2010. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. J. Virol. 84:12185-12199.
14. Jouvenet N, et al. 2009. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J. Virol. 83:1837-1844.
15. Sakuma T, Noda T, Urata S, Kawaoka Y, Yasuda J. 2009. Inhibition of Lassa and Marburg virus production by tetherin. J. Virol. 83:2382-2385.
16. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P. 2009. Tetherinmediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 106:2886-2891.
17. Mansouri M, et al. 2009. Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus. J. Virol. 83:9672-9681.
18. Pardieu C, et al. 2010. The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. PLoS Pathog. 6:e1000843.
19. Radoshitzky SR, et al. 2010. Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin. J. Virol. 84:10569-10580.
20. Weidner JM, et al. 2010. Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J. Virol. 84:12646-12657.
21. Willey RL, Maldarelli F, Martin MA, Strebel K. 1992. Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes. J. Virol. 66:226-234.
22. Magadán JG, et al. 2010. Multilayered mechanism of CD4 downregulation by HIV-1 Vpu involving distinct ER retention and ERAD targeting steps. PLoS Pathog. 6:e1000869.
23. Margottin F, et al. 1998. A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol. Cell 1:565-574.
24. Binette J, et al. 2007. Requirements for the selective degradation of CD4 receptor molecules by the human immunodeficiency virus type 1 Vpu protein in the endoplasmic reticulum. Retrovirology 4:75.
25. Butticaz C, Michielin O, Wyniger J, Telenti A, Rothenberger S. 2007. Silencing of both beta-TrCP1 and HOS (beta-TrCP2) is required to suppress human immunodeficiency virus type 1 Vpu-mediated CD4 downmodulation.J. Virol. 81:1502-1505.
26. Goffinet C, et al. 2009. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 5:285-297.
27. Mangeat B, et al. 2009. HIV-1 Vpu neutralizes the antiviral factor tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog. 5:e1000574.
28. Bartee E, McCormack A, Früh K. 2006. Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog. 2:e107.
29. Douglas JL, et al. 2009. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/tetherin via a {beta}-TrCPdependent mechanism. J. Virol. 83:7931-7947.
30. Dubé M, et al. 2010. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog. 6:e1000856.
31. Mitchell RS, et al. 2009. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog. 5:e1000450.
32. Miyagi E, Andrew AJ, Kao S, Strebel K. 2009. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc. Natl. Acad. Sci. U. S. A. 106:2868-2873.
33. Goffinet C, et al. 2010. Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu. J. Virol. 84:4089-4094.
34. Van Damme N, et al. 2008. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3:245-252.
35. Perez-Caballero D, et al. 2009. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139:499-511.
36. Dubé M, et al. 2009. Suppression of tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J. Virol. 83:4574-4590.
37. Hauser H, et al. 2010. HIV-1 Vpu and HIV-2 Env counteract BST-2/ tetherin by sequestration in a perinuclear compartment. Retrovirology 7:51.
38. Iwabu Y, et al. 2009. HIV-1 accessory protein Vpu internalizes cellsurface BST-2/tetherin through transmembrane interactions leading to lysosomes. J. Biol. Chem. 284:35060-35072.
39. Iwabu Y, Fujita H, Tanaka Y, Sata T, Tokunaga K. 2010. Direct internalization of cell-surface BST-2/tetherin by the HIV-1 accessory protein Vpu. Commun. Integr. Biol. 3:366-369.
40. Dubé M, Bego MG, Paquay C, Cohen ÉA. 2010. Modulation of HIV-1- host interaction: role of the Vpu accessory protein. Retrovirology 7:114.
41. Kuhl BD, Cheng V, Wainberg MA, Liang C. 2011. Tetherin and its viral antagonists. J. Neuroimmune Pharmacol. 6:188-201.
42. Goffinet C, Schmidt S, Kern C, Oberbremer L, Keppler OT. 2010. Endogenous CD317/tetherin limits replication of HIV-1 and murine leukemiabvirus in rodent cells and is resistant to antagonists from primate viruses. J. Virol. 84:11374-11384.
43. Andrew AJ, Miyagi E, Strebel K. 2011. Differential effects of human immunodeficiency virus type 1 Vpu on the stability of BST-2/tetherin. J. Virol. 85:2611-2619.
44. Ohtomo T, et al. 1999. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem. Biophys. Res. Commun. 258:583-591.
45. Keller GA, Siegel MW, Caras IW. 1992. Endocytosis of glycophospholipid-anchored and transmembrane forms ofCD4by different endocytic pathways. EMBO J. 11:863-874.
46. Nagy G, et al. 2006. Regulation of CD4 expression via recycling by HRES- 1/RAB4 controls susceptibility to HIV infection. J. Biol. Chem. 281: 34574-34591.
47. Signoret N, Pelchen-Matthews A, Mack M, Proudfoot AE, Marsh M. 2000. Endocytosis and recycling of the HIV coreceptor CCR5. J. Cell Biol. 151:1281-1294.
48. Kershaw T, Wavre-Shapton ST, Signoret N, Marsh M. 2009. Analysis of chemokine receptor endocytosis and intracellular trafficking. Methods Enzymol. 460:357-377.
49. Ochoa GC, et al. 2000. A functional link between dynamin and the actin cytoskeleton at podosomes. J. Cell Biol. 150:377-389.
50. Reid PA, Watts C. 1990. Cycling of cell-surface MHC glycoproteins through primaquine-sensitive intracellular compartments. Nature 346: 655-657.
51. van Weert AW, Geuze HJ, Groothuis B, Stoorvogel W. 2000. Primaquine interferes with membrane recycling from endosomes to the plasma membrane through a direct interaction with endosomes which does not involve neutralisation of endosomal pH nor osmotic swelling of endosomes. Eur. J. Cell Biol. 79:394-399.
52. Woods AJ, White DP, Caswell PT, Norman JC. 2004. PKD1/PKCmu promotes alphavbeta3 integrin recycling and delivery to nascent focal adhesions. EMBO J. 23:2531-2543.
53. Wildum S, Schindler M, Münch J, Kirchhoff F. 2006. Contribution of Vpu, Env, and Nef to CD4 down-modulation and resistance of human immunodeficiency virus type 1-infected T cells to superinfection. J. Virol. 80:8047-8059.
54. Habermann A, et al. 2010. CD317/tetherin is enriched in the HIV-1 envelope and downregulated from the plasma membrane upon virus infection. J. Virol. 84:4646-4658.
55. Schindler M, et al. 2010. Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue. Retrovirology 7:1.
56. Tervo HM, et al. 2011. beta-TrCP is dispensable for Vpu's ability to overcome the CD317/tetherin-imposed restriction to HIV-1 release. Retrovirology 8:9.
57. Hiebsch RR, Raub TJ, Wattenberg BW. 1991. Primaquine blocks transport by inhibiting the formation of functional transport vesicles. Studies in a cell-free assay of protein transport through the Golgi apparatus. J. Biol. Chem. 266:20323-20328.
58. Vincent MJ, Abdul Jabbar M. 1995. The human immunodeficiency virus type 1 Vpu protein: a potential regulator of proteolysis and protein transport in the mammalian secretory pathway. Virology 213:639-649.
59. Varthakavi V, et al. 2006. The pericentriolar recycling endosome plays a key role in Vpu-mediated enhancement of HIV-1 particle release. Traffic 7:298-307.
60. Blagoveshchenskaya AD, Thomas L, Feliciangeli SF, Hung CH, Thomas G. 2002. HIV-1 Nef downregulates MHC-I by a PACS-1- and PI3Kregulated ARF6 endocytic pathway. Cell 111:853-866.
61. Naughtin MJ, et al. 2010. The myotubularin phosphatase MTMR4 regulates sorting from early endosomes. J. Cell Sci. 123:3071-3083.
62. Johannes L, Popoff V. 2008. Tracing the retrograde route in protein trafficking. Cell 135:1175-1187.
63. Pfeffer SR. 2009. Multiple routes of protein transport from endosomes to the trans Golgi network. FEBS Lett. 583:3811-3816.
64. Vigan R, Neil SJ. 2010. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. J. Virol. 84:12958-12970.
65. Kobayashi T, et al. 2011. Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction and susceptibility. J. Virol. 85:932-945.
66. Rong L, et al. 2009. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. J. Virol. 83:7536-7546.
67. Gupta RK, et al. 2009. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog. 5:e1000443.
68. Fackler OT, Luo W, Geyer M, Alberts AS, Peterlin BM. 1999. Activation of Vav by Nef induces cytoskeletal rearrangements and downstream effector functions. Mol. Cell 3:729-739.